Tanya Collin-Histed
Research Subjects
Tanya Collin-Histed has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Elin Haf Davies
Aparito, a wholly owned subsidiary of Eli Lilly and Company
3 shared publicationsShoshana Revel-Vilk
Shaare Zedek Medical Center
3 shared publicationsKathleen Beusterien
Oracle Life Sciences
2 shared publicationsMadeline Stoodley
International Gaucher Alliance (IGA), London, UK
2 shared publications- A.I. Kiewiet
Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands
1 shared publication - Andre Balzekiene
International Gaucher Alliance, Vilnius, Lithuania
1 shared publication
Latest Publications
- Open Access
- 25 May 2026
- Published by Springer Nature in Research Square
Patient and caregiver burden of neuronopathic Gaucher disease: The GARDIAN Registry experience
Background Neuronopathic Gaucher disease (nGD) is a rare, progressive condition with substantial neurological and systemic burden and limited treatment options. Patient-reported outcome data are sparse and often rely on agnostic instruments that may not capture the full disease-specific impact. The Gaucher Registry for Development, Innovation and Analysis of Neuronopathic disease (GARDIAN) is a patient-led, multilingual, global registry designed to characterize disease burden over time and to evaluate nGD–specific patient- and caregiver-reported outcome measures. Results Between May 2022 and September 2025, 26 participants (10 patients and 16 caregivers) contributed baseline data; 14 participants provided at least one follow-up. Participants were recruited internationally. Most responses were provided by caregivers of children, reflecting early disease onset. Twenty-five patients had chronic nGD and one patient had acute nGD. At diagnosis, commonly reported non-neurological manifestations included splenomegaly, hepatomegaly, anaemia, abdominal distension, and thrombocytopenia, while neurological features included abnormal eye movements, strabismus, swallowing difficulties, ataxia, and laryngeal symptoms. At baseline, nearly all patients were receiving enzyme replacement therapy, in conjunction with supportive therapies such as calcium/vitamin D supplementation and antiepileptic medications. Some patients reported additional therapies including ambroxol, substrate reduction therapy, or gene therapy. Measures of mental health and quality of life indicated mild-to-moderate depressive and anxiety symptoms in a subset of respondents and moderate impairment in paediatric quality of life. Disease-specific outcome scores suggested a mildto-moderate overall impact, with social-emotional domains more affected than physical or self-care domains. Psychometric evaluation showed acceptable internal consistency for both disease-specific instruments and evidence of convergent validity with quality-of-life and disease-severity anchors, although estimates were imprecise due to small sample size and attrition. Conclusions GARDIAN demonstrates the feasibility and value of a patient-led global registry for nGD and provides early evidence supporting disease-specific patient- and caregiver-reported outcome measurement. Larger studies are needed to strengthen validation, improve precision, and inform future clinical care and therapeutic development.
- 25 May 2026
- Published by Springer Nature in Research Square
Open AccessPatient and caregiver burden of neuronopathic Gaucher disease: The GARDIAN Registry experience
Background Neuronopathic Gaucher disease (nGD) is a rare, progressive condition with substantial neurological and systemic burden and limited treatment options. Patient-reported outcome data are sparse and often rely on agnostic instruments that may not capture the full disease-specific impact. The Gaucher Registry for Development, Innovation and Analysis of Neuronopathic disease (GARDIAN) is a patient-led, multilingual, global registry designed to characterize disease burden over time and to evaluate nGD–specific patient- and caregiver-reported outcome measures. Results Between May 2022 and September 2025, 26 participants (10 patients and 16 caregivers) contributed baseline data; 14 participants provided at least one follow-up. Participants were recruited internationally. Most responses were provided by caregivers of children, reflecting early disease onset. Twenty-five patients had chronic nGD and one patient had acute nGD. At diagnosis, commonly reported non-neurological manifestations included splenomegaly, hepatomegaly, anaemia, abdominal distension, and thrombocytopenia, while neurological features included abnormal eye movements, strabismus, swallowing difficulties, ataxia, and laryngeal symptoms. At baseline, nearly all patients were receiving enzyme replacement therapy, in conjunction with supportive therapies such as calcium/vitamin D supplementation and antiepileptic medications. Some patients reported additional therapies including ambroxol, substrate reduction therapy, or gene therapy. Measures of mental health and quality of life indicated mild-to-moderate depressive and anxiety symptoms in a subset of respondents and moderate impairment in paediatric quality of life. Disease-specific outcome scores suggested a mildto-moderate overall impact, with social-emotional domains more affected than physical or self-care domains. Psychometric evaluation showed acceptable internal consistency for both disease-specific instruments and evidence of convergent validity with quality-of-life and disease-severity anchors, although estimates were imprecise due to small sample size and attrition. Conclusions GARDIAN demonstrates the feasibility and value of a patient-led global registry for nGD and provides early evidence supporting disease-specific patient- and caregiver-reported outcome measurement. Larger studies are needed to strengthen validation, improve precision, and inform future clinical care and therapeutic development.
- Open Access
- 20 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Exploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions
Background: Gaucher disease is a rare lysosomal storage disorder caused by insufficient activity of the enzyme β-glucocerebrosidase. This leads to the accumulation of fatty deposits in cells and tissues and damages multiple organ systems. Diagnosing Gaucher disease often involves a prolonged and challenging “diagnostic odyssey”. The International Gaucher Alliance (IGA) conducted a survey among individuals living with Gaucher disease, including patients, families, and caregivers, to investigate diagnostic challenges. Distributed primarily in English language, with a Spanish translation for relevant IGA members, the survey was completed by 142 respondents from 40 different countries between November 2024 and February 2025. The study aims to guide future efforts to promote timely diagnosis, access to expert management, and treatment before irreversible damage occurs. Early diagnosis also brings emotional and practical benefits, including informed family planning and support networks. Results: The survey revealed that diagnostic delays remain prevalent, with 58% of respondents waiting more than a year for diagnosis. Key contributors to delays included low awareness among physicians and inadequate communication between medical specialties. Common “red flag” symptoms identified in guidelines were often linked to eventual diagnosis, highlighting the need to educate healthcare professionals, especially those likely to encounter patients but not consider Gaucher disease (e.g., internal medicine specialists and gastroenterologists). Notably, 17% of respondents were not made aware of the genetic nature of Gaucher disease when they were diagnosed, potentially missing opportunities to identify affected relatives or influence family planning. Respondents suggested that increased awareness among healthcare professionals, expanded access to newborn screening, and greater availability of genetic and enzymatic testing could significantly accelerate the process. Conclusions: As well as continuing to engage in education and awareness activities for specialists that commonly diagnose Gaucher, targeted awareness campaigns for secondary care clinicians that do not commonly diagnose Gaucher, but are regularly seen in the journey to diagnosis could reduce diagnostic delays. Providing lay-friendly resources to help specialists explain genetic inheritance to newly diagnosed patients may enhance early family diagnoses. Country-specific surveys to understand local diagnostic experiences could shape tailored interventions. Lastly, advocacy efforts to address access barriers, should amplify patient voices and prioritise community needs.
- 20 February 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessExploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions
Background: Gaucher disease is a rare lysosomal storage disorder caused by insufficient activity of the enzyme β-glucocerebrosidase. This leads to the accumulation of fatty deposits in cells and tissues and damages multiple organ systems. Diagnosing Gaucher disease often involves a prolonged and challenging “diagnostic odyssey”. The International Gaucher Alliance (IGA) conducted a survey among individuals living with Gaucher disease, including patients, families, and caregivers, to investigate diagnostic challenges. Distributed primarily in English language, with a Spanish translation for relevant IGA members, the survey was completed by 142 respondents from 40 different countries between November 2024 and February 2025. The study aims to guide future efforts to promote timely diagnosis, access to expert management, and treatment before irreversible damage occurs. Early diagnosis also brings emotional and practical benefits, including informed family planning and support networks. Results: The survey revealed that diagnostic delays remain prevalent, with 58% of respondents waiting more than a year for diagnosis. Key contributors to delays included low awareness among physicians and inadequate communication between medical specialties. Common “red flag” symptoms identified in guidelines were often linked to eventual diagnosis, highlighting the need to educate healthcare professionals, especially those likely to encounter patients but not consider Gaucher disease (e.g., internal medicine specialists and gastroenterologists). Notably, 17% of respondents were not made aware of the genetic nature of Gaucher disease when they were diagnosed, potentially missing opportunities to identify affected relatives or influence family planning. Respondents suggested that increased awareness among healthcare professionals, expanded access to newborn screening, and greater availability of genetic and enzymatic testing could significantly accelerate the process. Conclusions: As well as continuing to engage in education and awareness activities for specialists that commonly diagnose Gaucher, targeted awareness campaigns for secondary care clinicians that do not commonly diagnose Gaucher, but are regularly seen in the journey to diagnosis could reduce diagnostic delays. Providing lay-friendly resources to help specialists explain genetic inheritance to newly diagnosed patients may enhance early family diagnoses. Country-specific surveys to understand local diagnostic experiences could shape tailored interventions. Lastly, advocacy efforts to address access barriers, should amplify patient voices and prioritise community needs.
- Open Access
- 21 July 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-11
A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
Background: Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder. GD types 2 and 3 are known as neuronopathic Gaucher disease (nGD) because they have brain involvement that progresses over time. Implementing a systematic approach to the collection of real-world clinical and patient-relevant outcomes data in nGD presents an opportunity to fill critical knowledge gaps and ultimately help healthcare providers in the management of this patient population. This paper summarizes the development of a patient-initiated Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease (GARDIAN). Methods: The International Gaucher Alliance led the GARDIAN planning, including governance, scope, stakeholder involvement, platform, and reporting. Registry element input was determined in a series of meetings with clinical experts, patients, and caregivers, who identified key clinical variables and the draft content of nGD patient-reported outcomes (PRO) and observer-reported outcomes (ObsRO) focusing on symptoms, patient physical and emotional functioning. These were then tested in cognitive interviews with patients with nGD (> 12 years of age) and caregivers. Results: Core registry data elements (n = 138) were identified by seven global clinical experts from Egypt, Germany, Israel, Japan, United Kingdom (UK), and United State (US) and reviewed via online Delphi method by 14 additional clinicians with experience of nGD from six countries and three pharmaceutical representatives. The elements were consistent with those identified via interviews with 10 patients/caregivers with nGD from Japan, Sweden, UK, and US. Key domains identified were demographics, diagnostic information, health status, clinical symptomatology, laboratory testing, treatment, healthcare resource utilization, aids/home improvements, and patient/caregiver burden and quality of life, specifically physical functioning, self-care, daily and social activities, emotional impacts, support services, and caregiver-specific impacts. Nine caregivers and six patients from the US, UK, China, Mexico, Egypt, and Japan participated in the cognitive interviews that informed revisions to ensure that all items are understandable and interpreted as intended. Conclusions: The comprehensive set of clinical and patient relevant outcomes data, developed collaboratively among all stakeholders, to be reported using GARDIAN will bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.
- 21 July 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-11
Open AccessA global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
Background: Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder. GD types 2 and 3 are known as neuronopathic Gaucher disease (nGD) because they have brain involvement that progresses over time. Implementing a systematic approach to the collection of real-world clinical and patient-relevant outcomes data in nGD presents an opportunity to fill critical knowledge gaps and ultimately help healthcare providers in the management of this patient population. This paper summarizes the development of a patient-initiated Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease (GARDIAN). Methods: The International Gaucher Alliance led the GARDIAN planning, including governance, scope, stakeholder involvement, platform, and reporting. Registry element input was determined in a series of meetings with clinical experts, patients, and caregivers, who identified key clinical variables and the draft content of nGD patient-reported outcomes (PRO) and observer-reported outcomes (ObsRO) focusing on symptoms, patient physical and emotional functioning. These were then tested in cognitive interviews with patients with nGD (> 12 years of age) and caregivers. Results: Core registry data elements (n = 138) were identified by seven global clinical experts from Egypt, Germany, Israel, Japan, United Kingdom (UK), and United State (US) and reviewed via online Delphi method by 14 additional clinicians with experience of nGD from six countries and three pharmaceutical representatives. The elements were consistent with those identified via interviews with 10 patients/caregivers with nGD from Japan, Sweden, UK, and US. Key domains identified were demographics, diagnostic information, health status, clinical symptomatology, laboratory testing, treatment, healthcare resource utilization, aids/home improvements, and patient/caregiver burden and quality of life, specifically physical functioning, self-care, daily and social activities, emotional impacts, support services, and caregiver-specific impacts. Nine caregivers and six patients from the US, UK, China, Mexico, Egypt, and Japan participated in the cognitive interviews that informed revisions to ensure that all items are understandable and interpreted as intended. Conclusions: The comprehensive set of clinical and patient relevant outcomes data, developed collaboratively among all stakeholders, to be reported using GARDIAN will bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.
- Open Access
- 5 April 2023
- Published by Springer Nature in Research Square
A Global Neuronopathic Gaucher Disease Registry (GARDIAN): A Patient-Led Initiative
Background Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder. GD types 2 and 3 are known as neuronopathic Gaucher disease (nGD) because they have brain involvement that progresses over time. Implementing a systematic approach to the collection of real-world clinical and patient-relevant outcomes data in nGD presents an opportunity to fill critical knowledge gaps and ultimately help healthcare providers in the management of this patient population. This paper summarizes the development of a patient-initiated Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease (GARDIAN). Methods The International Gaucher Alliance led the GARDIAN planning, including governance, scope, stakeholder involvement, platform, and reporting. Registry element input was determined in a series of meetings with clinical experts, patients, and caregivers, who identified key clinical variables and the draft content of nGD patient-reported outcomes (PRO) and observer-reported outcomes (ObsRO) focusing on symptoms, patient physical and emotional functioning. These were then tested in cognitive interviews with patients with nGD (> 12 years of age) and caregivers. Results Core registry data elements (n = 138) were identified by seven global clinical experts from Egypt, Germany, Israel, Japan, United Kingdom (UK), and United State (US) and reviewed via online Delphi method by 14 additional clinicians with experience of nGD from six countries and three pharmaceutical representatives. The elements were consistent with those identified via interviews with 10 patients/caregivers with nGD from Japan, Sweden, UK, and US. Key domains identified were demographics, diagnostic information, health status, clinical symptomatology, laboratory testing, treatment, healthcare resource utilization, aids/home improvements, and patient/caregiver burden and quality of life, specifically physical functioning, self-care, daily and social activities, emotional impacts, support services, and caregiver-specific impacts. Nine caregivers and six patients from the US, UK, China, Mexico, Egypt, and Japan participated in the cognitive interviews that informed revisions to ensure that all items are understandable and interpreted as intended. Conclusions The comprehensive set of clinical and patient relevant outcomes data, developed collaboratively among all stakeholders, to be reported using GARDIAN will bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.
- 5 April 2023
- Published by Springer Nature in Research Square
Open AccessA Global Neuronopathic Gaucher Disease Registry (GARDIAN): A Patient-Led Initiative
Background Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder. GD types 2 and 3 are known as neuronopathic Gaucher disease (nGD) because they have brain involvement that progresses over time. Implementing a systematic approach to the collection of real-world clinical and patient-relevant outcomes data in nGD presents an opportunity to fill critical knowledge gaps and ultimately help healthcare providers in the management of this patient population. This paper summarizes the development of a patient-initiated Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease (GARDIAN). Methods The International Gaucher Alliance led the GARDIAN planning, including governance, scope, stakeholder involvement, platform, and reporting. Registry element input was determined in a series of meetings with clinical experts, patients, and caregivers, who identified key clinical variables and the draft content of nGD patient-reported outcomes (PRO) and observer-reported outcomes (ObsRO) focusing on symptoms, patient physical and emotional functioning. These were then tested in cognitive interviews with patients with nGD (> 12 years of age) and caregivers. Results Core registry data elements (n = 138) were identified by seven global clinical experts from Egypt, Germany, Israel, Japan, United Kingdom (UK), and United State (US) and reviewed via online Delphi method by 14 additional clinicians with experience of nGD from six countries and three pharmaceutical representatives. The elements were consistent with those identified via interviews with 10 patients/caregivers with nGD from Japan, Sweden, UK, and US. Key domains identified were demographics, diagnostic information, health status, clinical symptomatology, laboratory testing, treatment, healthcare resource utilization, aids/home improvements, and patient/caregiver burden and quality of life, specifically physical functioning, self-care, daily and social activities, emotional impacts, support services, and caregiver-specific impacts. Nine caregivers and six patients from the US, UK, China, Mexico, Egypt, and Japan participated in the cognitive interviews that informed revisions to ensure that all items are understandable and interpreted as intended. Conclusions The comprehensive set of clinical and patient relevant outcomes data, developed collaboratively among all stakeholders, to be reported using GARDIAN will bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.
- Open Access
- 1 February 2018
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 68, 203-208
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
- 1 February 2018
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 68, 203-208
Open AccessManagement goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
- Open Access
- 2 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-14
The European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns
The European Gaucher Alliance (EGA) was established in 1994 and constituted in 2008 as an umbrella group supporting patient organisations for Gaucher disease. Every two years, the EGA conducts a questionnaire survey of member associations to help develop its priorities and annual work programme. Results of the latest survey are presented. Between June 2012 and April 2013, the 36 members and associate members of the EGA were asked to complete a questionnaire detailing membership numbers, disease specific treatments used by patients, means of access to treatment, availability of treatment centres and home infusions, sources of support for patients with Gaucher disease, patient organisations’ activities, collaborations, funding sources and any issues of concern. Questionnaires completed in 2012 were revised in January 2013 and responses analysed between July and September 2013. Thirty three members returned data on one or more questions. Findings identified inequalities in access to treatment both within and between members’ countries. Three of 27 countries, for which data were available, relied totally on humanitarian aid for treatment and 6% of untreated patients in 20 countries were untreated because of funding issues, a situation many feared would worsen with deteriorating economic climates. Access to treatment and reimbursement represented 45% of members’ concerns, while 35% related to access to specialist treatment centres, home infusions and doctors with expertise in Gaucher disease. Member associations’ main activities centred on patient support (59% of responses) and raising awareness of Gaucher disease and patients’ needs amongst the medical community, government and healthcare decision makers and the general public (34% of responses). Twenty one (78% of respondents) indicated they were the only source of help for Gaucher disease patients in their country. For many, activities were constrained by funds; two members had no external funding source. Activities were maximised through collaboration with other patient organisations and umbrella organisations for rare diseases. The survey provided a snapshot’ of the situation for patients and families affected by Gaucher disease, helping the EGA direct its activities into areas of greatest need.
- 2 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-14
Open AccessThe European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns
The European Gaucher Alliance (EGA) was established in 1994 and constituted in 2008 as an umbrella group supporting patient organisations for Gaucher disease. Every two years, the EGA conducts a questionnaire survey of member associations to help develop its priorities and annual work programme. Results of the latest survey are presented. Between June 2012 and April 2013, the 36 members and associate members of the EGA were asked to complete a questionnaire detailing membership numbers, disease specific treatments used by patients, means of access to treatment, availability of treatment centres and home infusions, sources of support for patients with Gaucher disease, patient organisations’ activities, collaborations, funding sources and any issues of concern. Questionnaires completed in 2012 were revised in January 2013 and responses analysed between July and September 2013. Thirty three members returned data on one or more questions. Findings identified inequalities in access to treatment both within and between members’ countries. Three of 27 countries, for which data were available, relied totally on humanitarian aid for treatment and 6% of untreated patients in 20 countries were untreated because of funding issues, a situation many feared would worsen with deteriorating economic climates. Access to treatment and reimbursement represented 45% of members’ concerns, while 35% related to access to specialist treatment centres, home infusions and doctors with expertise in Gaucher disease. Member associations’ main activities centred on patient support (59% of responses) and raising awareness of Gaucher disease and patients’ needs amongst the medical community, government and healthcare decision makers and the general public (34% of responses). Twenty one (78% of respondents) indicated they were the only source of help for Gaucher disease patients in their country. For many, activities were constrained by funds; two members had no external funding source. Activities were maximised through collaboration with other patient organisations and umbrella organisations for rare diseases. The survey provided a snapshot’ of the situation for patients and families affected by Gaucher disease, helping the EGA direct its activities into areas of greatest need.